Revelation Biosciences Q4 EPS $(8.33) Beats $(13.77) Estimate
Portfolio Pulse from Happy Mohamed
Revelation Biosciences reported a Q4 EPS loss of $(8.33), surpassing the analyst consensus estimate of $(13.77) by 39.51%. This marks an 84.31% improvement over the previous year's Q4 loss of $(53.10) per share.
March 22, 2024 | 8:22 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Revelation Biosciences reported a smaller than expected Q4 EPS loss of $(8.33), outperforming the consensus estimate of $(13.77) and showing significant improvement from last year.
Beating the EPS estimate by a significant margin and showing a substantial year-over-year improvement in losses indicates a positive trajectory for Revelation Biosciences. This performance could lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100